Gothenburg-based company acquired by Norwegian diagnostics group

Gentian Diagnostics acquires Gothenburg-based Getica.

NorthX Biologics Matfors AB

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

IVI’s Director General on establishing in Sweden: Will need up to 40 employees

The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Je...

The perfect formula for decision-making

No one has the luxury not to take a decision, writes Helena Strigård at Swedenbio.

Cytel Inc acquires the SDS Group

The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consult...

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

Amerikansk vård-vd sköts till döds på öppen gata

Vd:n för det amerikanska hälsovårdsbolaget United Healthcare, Brian Thompson, sköts ihjäl på Manhattan i New York på onsdagsmorgonen.

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden

Lonza

Just four weeks to a concept for an emergency ventilator

The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...

Elypta awarded one million USD from the Star Trek creator’s foundation

Swedish company Elypta, which develops methods for early cancer detection, has been awarded one million USD from an unexpected source: a foundation set up in me...

Mastering Urine Microscopy

On-demand Webinar: Microscopy in urinalysis.

Meeting with focus on South Korea and Japan’s life sciences

Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...

EU Pharmaceutical Legislation Reform

The EU's Pharmaceutical Legislation Reform, proposed by the commission within the European Health Union, aims to establish a citizen-centric framework to enhanc...

Save time and money !

Festo Digital engineering tools helps you to calculate the most cost and efficient solution for your application for free

Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...

Pfizer’s record year – topped the $100 billion mark

In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson...

Noxious parasite forms hybrids and deceives the immune system

The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to decei...

Mavatar AB

Lösning hittad för Orexos patenttvist

En långdragen patenttvist mellan Uppsalabolaget Orexo och indiska Sun Pharmaceutical Industries är nu löst genom förlikning.

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages

For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridicul...

Thomas Eldered: ”Innovation is the key”

Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.